Activating mutations of ERBB2, which are mainly observed in the tyrosine kinase domain, lead to increased cell proliferation in vitro, rapid tumor growth in vivo, and sensitivity to HER2 targeted therapy, indicating their role as driver mutations [7, 8, 12]. This evidence concerns the gene ERBB2 and neoplasm.